Scilex Holding (NASDAQ:SCLX - Get Free Report) insider Jaisim Shah purchased 30,000 shares of Scilex stock in a transaction dated Wednesday, December 18th. The shares were purchased at an average price of $0.46 per share, with a total value of $13,800.00. Following the completion of the transaction, the insider now directly owns 139,333 shares in the company, valued at approximately $64,093.18. This represents a 27.44 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link.
Jaisim Shah also recently made the following trade(s):
- On Tuesday, October 29th, Jaisim Shah acquired 32,000 shares of Scilex stock. The shares were acquired at an average cost of $0.99 per share, with a total value of $31,680.00.
- On Wednesday, October 16th, Jaisim Shah acquired 30,000 shares of Scilex stock. The shares were acquired at an average cost of $0.99 per share, with a total value of $29,700.00.
Scilex Price Performance
NASDAQ:SCLX opened at $0.46 on Thursday. Scilex Holding has a 1-year low of $0.44 and a 1-year high of $2.63. The business has a 50 day moving average of $0.75 and a 200 day moving average of $1.15. The company has a market capitalization of $88.11 million, a price-to-earnings ratio of -0.32 and a beta of 0.96.
Institutional Investors Weigh In On Scilex
WARNING: “Buffett Indicator” flashing for first time in 50 years
From Behind the Markets | Ad
Warren Buffett has sold a staggering $97 billion worth of stocks this year...
But why?
Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash.
His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.
Take these 4 steps today to protect your retirement NOW
A number of institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company purchased a new position in Scilex in the 2nd quarter worth $25,000. Bank of New York Mellon Corp bought a new position in Scilex during the 2nd quarter worth approximately $31,000. Donald L. Hagan LLC increased its stake in Scilex by 15.4% in the 3rd quarter. Donald L. Hagan LLC now owns 130,792 shares of the company's stock worth $121,000 after purchasing an additional 17,500 shares during the period. XTX Topco Ltd lifted its position in Scilex by 321.4% in the second quarter. XTX Topco Ltd now owns 105,431 shares of the company's stock valued at $203,000 after purchasing an additional 80,409 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its stake in shares of Scilex by 3.5% during the third quarter. Janus Henderson Group PLC now owns 534,302 shares of the company's stock valued at $494,000 after purchasing an additional 17,848 shares during the period. Hedge funds and other institutional investors own 69.67% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts have issued reports on SCLX shares. HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Scilex in a research report on Monday, October 21st. Alliance Global Partners began coverage on Scilex in a research note on Wednesday, October 16th. They issued a "buy" rating and a $14.00 target price on the stock.
Read Our Latest Stock Analysis on Scilex
Scilex Company Profile
(
Get Free Report)
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
